• Opinion
• [Reporter’s View] Still no news on SGLT-2 combo reimb.
• by Eo, Yun-Ho Apr 6, 2022 06:06am

• Opinion
• [Reporter's view] Commercialization of innovative new drugs
• by Lee, Tak-Sun Apr 5, 2022 05:58am

• Opinion
• [Reporter’s View] Regrets in GOV's COVID-19 responses
• by Mar 30, 2022 06:09am

• Opinion
• [Reporter’s View] Specific healthcare plans are required
• by Lee, Jeong-Hwan Mar 24, 2022 05:54am

• Opinion
• [Reporter's view] Our attitude toward personalized txs
• by Eo, Yun-Ho Mar 23, 2022 05:51am

• Opinion
• [Reporter’s View] Keytruda’s ‘trade-off’ reimbursement
• by Eo, Yun-Ho Mar 7, 2022 05:49am

• Opinion
• [Reporter's view] Consistency in the post evaluation
• by Lee, Tak-Sun Mar 7, 2022 05:49am

• Opinion
• [Reporter’s View] Why Big Pharmas 'select and focus'
• by Mar 2, 2022 05:54am

• Opinion
• [Reporter's view]Will it be different this time?
• by Kim, Jin-Gu Feb 23, 2022 05:49am

• Opinion
• [Reporter’s View] Why set deadlines in pricing negotiations
• by Eo, Yun-Ho Feb 17, 2022 05:53am